SCHEMBL2117300

SCHEMBL2117300

COc1ccc(S(=O)(=O)Nc2cc(-n3cccc3)ccc2C)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KEAP1 Q14145 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GHSR Q92847 3/20 0.40
P2RX7 Q99572 2/20 0.39
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
BRD4 O60885 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
NAMPT P43490 1/20 0.36
SLC40A1 Q9NP59 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116719 0.80 P2RX7 (0.39) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2117726 0.79 P2RX7 (0.40) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2118122 0.78 MAPT (0.48) MAPTALDH1A1KEAP1CYP2C9TSHR
SCHEMBL2119327 0.78 MEN1 (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2582089 0.76 MAPT (0.47) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2119955 0.76 KMT2A (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2117318 0.76 MEN1 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2122490 0.75 SLC40A1 (0.49) MAPTMEN1KMT2APKMTSHR
SCHEMBL2118706 0.75 TRIM24 (0.45) MAPTALDH1A1KEAP1CYP2C9TSHR
SCHEMBL2118512 0.75 GHSR (0.45) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885ALDH1A1 1063/4885MEN1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.